Roger Dansey is a seasoned pharma executive with extensive experience in clinical development and oncology. They served as Vice President of Hematology/Oncology Clinical Development at Gilead Sciences from 2012 to 2014, and held multiple leadership roles at major companies including Amgen, Merck, and Seagen. Currently, they are the Interim Chief Oncology Officer at Pfizer, where they have been since 2025. Dansey earned their MBBCh and multiple master's degrees at the University of the Witwatersrand, furthering their expertise in internal medicine.
This person is not in the org chart
This person is not in any teams
This person is not in any offices